Pure Global AI
NCT06286618Recruitment Completed

Nutrition360: Moving to Integrated and Holistic Disease Prevention Among Underserved Mississippians

Moving to Integrated and Holistic Disease Prevention Among Underserved Mississippians
University of Southern MississippiClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
Cardiovascular Diseases
Drug/Device/Intervention
Psychosocial Intervention
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University of Southern Mississippi
Location
Hattiesburg, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2022
End date
Aug 31, 2024
Enrollment
24 participants
Primary outcome

Participant Burden

Summary

The objective for the study is to implement a pilot study to establish essential components
 to address diet quality in healthcare settings and examine what value an integrated service
 model delivery has for the primary prevention of cardiometabolic diseases with an initial
 focus on dietary behaviors. This objective will be met by 1: Utilizing a multiphase
 optimization study design to select and optimize essential components to address diet
 behaviors and 2: Comparing an integrated and referral-based delivery model for
 healthcare-based strategies that address structural and psychosocial barriers to a healthy
 diet for racial/ethnic minority, marginalized and disadvantaged background young to middle
 aged adult populations in Mississippi.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseOther ill-defined heart diseasesHeart disease, unspecifiedObservation for other suspected cardiovascular diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06286618
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06286618 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Southern Mississippi and is currently Recruitment Completed. The study focuses on Cardiovascular Diseases. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.